- Home
- ALAR vs FHTX Comparison
ALAR vs FHTX Comparison
Compare ALAR & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALAR
- FHTX
- Stock Information
- Founded
- ALAR 2013
- FHTX 2015
- Country
- ALAR Israel
- FHTX United States
- Employees
- ALAR N/A
- FHTX N/A
- Industry
- ALAR Computer Software: Prepackaged Software
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- ALAR Technology
- FHTX Health Care
- Exchange
- ALAR Nasdaq
- FHTX Nasdaq
- Market Cap
- ALAR 98.9M
- FHTX 271.5M
- IPO Year
- ALAR 2018
- FHTX 2020
- Fundamental
- Price
- ALAR $11.67
- FHTX $5.80
- Analyst Decision
- ALAR Strong Buy
- FHTX Strong Buy
- Analyst Count
- ALAR 1
- FHTX 8
- Target Price
- ALAR $15.00
- FHTX $12.63
- AVG Volume (30 Days)
- ALAR 155.4K
- FHTX 153.8K
- Earning Date
- ALAR 08-25-2025
- FHTX 08-07-2025
- Dividend Yield
- ALAR N/A
- FHTX N/A
- EPS Growth
- ALAR N/A
- FHTX N/A
- EPS
- ALAR 0.07
- FHTX N/A
- Revenue
- ALAR $30,581,000.00
- FHTX $23,504,000.00
- Revenue This Year
- ALAR N/A
- FHTX $33.60
- Revenue Next Year
- ALAR $12.28
- FHTX $5.87
- P/E Ratio
- ALAR $17.83
- FHTX N/A
- Revenue Growth
- ALAR 4.67
- FHTX N/A
- 52 Week Low
- ALAR $5.45
- FHTX $2.95
- 52 Week High
- ALAR $31.43
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- ALAR 51.97
- FHTX 69.02
- Support Level
- ALAR $11.67
- FHTX $4.78
- Resistance Level
- ALAR $14.63
- FHTX $6.13
- Average True Range (ATR)
- ALAR 0.80
- FHTX 0.37
- MACD
- ALAR -0.34
- FHTX 0.08
- Stochastic Oscillator
- ALAR 15.49
- FHTX 78.15
About ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.